Advances in the development of Wnt/β-catenin signaling inhibitors

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• The Wnt/β-catenin signaling pathway is crucial for cell functions like proliferation and differentiation.
• Its aberrant activation is linked to various cancers, including colorectal, pancreatic, and gastric cancers.
• This pathway represents a significant therapeutic target in oncology.

Purpose of the Study:

• To review the latest advancements in Wnt/β-catenin pathway inhibitors for cancer therapy.
• To explore novel therapeutic strategies and future directions in targeting this pathway.

Main Methods:

• Development of small molecules, peptides, and nucleic acid-based therapies.
• Application of antibody-based therapies to block ligand-receptor interactions.
• Exploration of innovative approaches like allosteric inhibitors and PROTACs.

Main Results:

• Various inhibitors have been developed to suppress cancer cell growth by disrupting Wnt/β-catenin pathway interactions.
• Antibody-based therapies show potential in blocking pathway signaling.
• Newer strategies like PROTACs and peptide inhibitors address existing challenges.

Conclusions:

• Targeting the Wnt/β-catenin pathway is a promising strategy for cancer treatment.
• Ongoing research focuses on developing more effective and safer inhibitors.
• Innovative approaches hold potential for overcoming therapeutic challenges and advancing cancer therapy.